Literature DB >> 18406872

Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements.

Valeria A S De Melo1, Dragana Milojkovic, David Marin, Jane F Apperley, Elisabeth P Nacheva, Alistair G Reid.   

Abstract

Deletions at the t(9;22) breakpoint regions, found in 15% of chronic myeloid leukemia patients (CML) with an overt Philadelphia (Ph) translocation, are associated with an adverse disease prognosis in patients receiving interferon-alpha therapy. The incidence of deletions has been shown to vary for different cytogenetic subgroups of CML, with a significantly higher incidence of deletion in patients with a variant Ph translocation. To date, however, the frequency of such deletions in the subgroup of CML patients in whom the BCR/ABL1 fusion arises via submicroscopic chromosomal insertion (masked Ph) has not been investigated. We report the evaluation of 14 patients with masked Ph-positive CML for the presence of deletions extending 3' from BCR and 5' from ABL1 using two triple-color BCR/ABL probes. Deletions were identified in 3 patients (21%), encompassing sequences 5' to ABL1 in two of these and sequences 3' to BCR in the remaining patient, thus demonstrating that the phenomenon is a significant feature of the masked Ph CML subgroup. Furthermore, our findings are consistent with the notion that loss of genomic material is a potential side effect of any DNA breakage event at the 9q34.1 and 22q11.2 chromosomal regions, regardless of the subsequent mechanism of chromosomal rearrangement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406872     DOI: 10.1016/j.cancergencyto.2008.01.007

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.

Authors:  Lina Shao; Sung-Hae L Kang; Jian Li; Patricia Hixson; Jesalyn Taylor; Svetlana A Yatsenko; Chad A Shaw; Aleksandar Milosavljevic; Chung-Che Chang; Sau Wai Cheung; Ankita Patel
Journal:  J Mol Diagn       Date:  2010-08-19       Impact factor: 5.568

2.  Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients.

Authors:  Ayda Bennour; Hatem Bellâaj; Yosra Ben Youssef; Moez Elloumi; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-08       Impact factor: 4.553

3.  Persistence of derivative chromosome 22 after achieving a major molecular response in chronic myeloid leukemia with a cryptic BCR-ABL1 fusion gene.

Authors:  Hiromichi Matsushita; Atsuko Masukawa; Satoshi Arakawa; Yoshiaki Ogawa; Satomi Asai; Miharu Yabe; Kiyoshi Ando; Hayato Miyachi
Journal:  Int J Hematol       Date:  2009-12-10       Impact factor: 2.490

4.  Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.

Authors:  Francesco Albano; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Paola Casieri; Antonella Russo Rossi; Laura Vicari; Vincenzo Liso; Mariano Rocchi; Giorgina Specchia
Journal:  Mol Cancer       Date:  2010-05-25       Impact factor: 27.401

5.  Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.

Authors:  Simona Luatti; Carmen Baldazzi; Giulia Marzocchi; Gaia Ameli; Maria Teresa Bochicchio; Simona Soverini; Fausto Castagnetti; Mario Tiribelli; Gabriele Gugliotta; Giovanni Martinelli; Michele Baccarani; Michele Cavo; Gianantonio Rosti; Nicoletta Testoni
Journal:  Oncotarget       Date:  2017-05-02

6.  Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.

Authors:  M Sigl; S Spoerl; S Schnittger; J Meissner; C Rummelt; C Peschel; J Duyster; A D Ho; N von Bubnoff
Journal:  Blood Cancer J       Date:  2013-03-08       Impact factor: 11.037

7.  FISH mapping of Philadelphia negative BCR/ABL1 positive CML.

Authors:  Anna Virgili; Diana Brazma; Alistair G Reid; Julie Howard-Reeves; Mikel Valgañón; Anastasios Chanalaris; Valeria As De Melo; David Marin; Jane F Apperley; Colin Grace; Ellie P Nacheva
Journal:  Mol Cytogenet       Date:  2008-07-18       Impact factor: 2.009

8.  Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy.

Authors:  Stefania Aliano; Gabriella Cirmena; Giuseppina Fugazza; Roberto Bruzzone; Claudia Palermo; Mario Sessarego
Journal:  Leuk Res Rep       Date:  2013-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.